Scancell Holdings plc (LON:SCLP – Get Free Report) rose 7% during trading on Thursday after an insider bought additional shares in the company. The company traded as high as GBX 10.43 ($0.14) and last traded at GBX 9.90 ($0.13). Approximately 1,065,551 shares changed hands during mid-day trading, an increase of 21% from the average daily volume of 878,498 shares. The stock had previously closed at GBX 9.25 ($0.13).
Specifically, insider Martin Diggle acquired 44,944 shares of the firm’s stock in a transaction on Tuesday, May 20th. The stock was purchased at an average cost of GBX 9 ($0.12) per share, with a total value of £4,044.96 ($5,475.78).
Scancell Price Performance
The business has a 50 day moving average price of GBX 9.41 and a two-hundred day moving average price of GBX 10.19. The stock has a market cap of £102.54 million, a PE ratio of -15.18 and a beta of 0.35. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42.
Scancell Company Profile
Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.
Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.
Read More
- Five stocks we like better than Scancell
- Best Energy Stocks – Energy Stocks to Buy Now
- Pfizer’s 7.5% Dividend: Income Haven or House of Cards?
- What Are Treasury Bonds?
- 3 Trades Members of Congress Are Making Right Now
- Stock Average Calculator
- TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
